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ABSTRACT 
 
Background. Lower-limb ulcers represent a debilitating phenomenon with a prevalence 
of 3% in the people over 65 years old. The ulcers are particularly severe in diabetic 
patients where they tend to become chronic non-healing wounds, leading to a series of 
clinical complications. Nowadays, although surgical revascularization remains the gold 
standard therapeutical option for wound healing, many new therapeutic approaches are 
under development to facilitate and accelerate the recovery of the injured tissues. In this 
context, the use of growth factors, mesenchymal stem cells and autologous fibroblasts 
are acquiring increasingly importance. Based on these evidences, this study was aimed 
to test one of the proangiogenic factors, HGF, on hVW-MSCs isolated from human 
arteries and compare the differentiation potential between hVW-MSC and the stromal 
counterpart (dermal fibroblasts and myofibroblasts). 
Materials and methods. HGF effect on hVW-MSCs was studied; proliferation, 
migration, motility, angiogenic induction and modulation of tissue remodeling and 
inflammation markers were specific areas investigated. HGF was also tested on MSCs 
recovered from abdominal aortic aneurysms (AAA-MSCs). Furthermore, assays of 
angiogenic and adipogenic differentiation potential were established on hVW-MSCs, 
dermal fibroblasts and myofibroblasts. 
Results. HGF stimulates migration, motility and angiogenic differentiation of hVW-
MSCs, but it has no effect on proliferation and tissue remodeling and inflammation 
markers. Results on AAA-MSCs show that HGF decreases the expression of 
inflammatory cytokines and positively modulate some markers involved in tissue 
remodeling. Finally, hVW-MSCs own a higher angiogenic and adipogenic commitment 
compared to dermal fibroblasts and myofibroblasts. 
Discussion. The combined use of HGF and hVW-MSCs, especially because of their 
high differentiation potential, represents a promising therapeutic strategy, in order to 
facilitate the healing of unresponsive vascular ulcers. 
Keywords: ulcers; wound healing; HGF; hVW-MSCs; fibroblasts; myofibroblasts; 
differentiation potential. 
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Lower-extremity ulcerations  
 
Lower-extremity ulceration is a debilitating phenomenon with prevalence from 1 to 
3,6%, in patients over 65 years of age it is up to 5%, particularly in Western countries 
(N. J. M. London et R. Donnelly, 2000; G. Spentzouris et al, 2009). Lower limb ulcers 
affect not only the quality of life of the patients, but also the whole society, since the 
healthcare expenditures for preventing, treating and decelerating the development of 
lower limb ulcers are really great. 
There are many different types of ulcers, according to several causes: venous, arterial, 
neurotrophic, lymphatic, malignant, infectious, medication induced, inflammatory, 
drug-induced and due to autoimmune diseases. 
Most leg ulcers are caused by venous disease alone (72%) (D. J. Adam et al, 2003); 
these occur above the medial and the lateral malleoli, and the main mechanisms behind 
venous ulcers are reflux and/or venous outflow obstruction which causes stasis and 
venous hypertension (A. N. Nicolaides et al, 2008). It occurs an increased ambulatory 
venous pressure, which is transmitted to the capillaries of the subcutaneous tissues, 
which may result into a fluid passage in the extravasal environment and into an 
accumulation of macromolecules such hemoserine and fibrinogen; these last hinder the 
gas exchange, while the leucocytes are activated bringing to cytolysis, skin damage and 
ulcer development (A. N. Nicolaides et al, 1993; J.J. Bergan et al, 2006). 
Ulcers due to arterial disease are the second most common (10-30%) (M. K. Lazarides  
et al, 2007; J. R. Mekkes et al, 2003; R. Renner et al, 2008). Many arterial pathologies 
can lead to arterial ulcers, but the main cause is arterial obstruction; peripheral arterial 
disease (PAD) is a major contributor, but also thrombotic events, aneurysm, plaques and 
hypercoagulable state (L. R. Leon et al,2005). Compensation mechanisms are activated 
in arterial ulcers, such as the blood viscosity, the aggregation of platelets and the 
erythrocyte deformability that leading to a condition of critical ischemia; also in this 
case, the endothelial damage increases the flow of liquids and fibrinogen in the 
interstitial area, resulting into tissue hypoxia and activating leucocytes and platelets, 
which obstruct capillaries and arterioles.  
The next most common ulcers are neuropathic in origin (15-25%) (M. K. Lazarides et 
al, 2007; J. R. Mekkes et al, 2003; R. Renner et al, 2008). Usually, it is about patients 
with diabetes and the neuropathy is threefold: motor, sensory and autonomic; the 
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neuropathy coupled with diabetes creates the perfect environment for a non-healing 
ulcer.  
Ulcerations may also be due to infectious causes (mostly bacteria, but also viruses, 
parasites and fungi), or mixed etiology causes (G. Spentzouris et al, 2009; D. J. Adam et 
al, 2003).  
Rarely it is possible to develop ulceration due to lymphatic cause (G. Spentzouris et al, 
2009).  
Recently it has been shown that super-obese patients may get venous ulcers without 
having venous disease detected (F. Jr Padberg et al, 2003).  
Finally each ulcer has different characteristics and clinical history, but surely an 
accurate diagnosis of etiology, often multifactorial, is essential before beginning 
treatment, in order to improve health of the patient and reduce costs and use of 
resources (Figure 1).  
 
 
 
Figure 1: Examples of lower limb ulcers. 
 
 
  Introduction 
  12 
Peripheral arterial occlusive disease (PAOD) 
 
Peripheral artery disease (PAD) or Peripheral arterial occlusive disease (PAOD) 
represents a shrinkage of the arteries that commonly affects the legs. PAOD affect 15-
20% of people older 70 years of age, although 70-80% is asymptomatic (F. J. Serrano 
Hernando
 
et A. M. Conejeroand, 2007). PAOD is a type of vascular disease in which 
the fatty deposits in the inner walls of arteries blocking the normal blood flow (Figure 
2). The main development sites of PAOD are the iliac artery, the femoral artery, the 
popliteal artery and the tibial arteries; the disease leads to the obstruction of the arteries 
that come to the kidneys, stomach, arms, legs and feet, and, if untreated, can lead the 
patient to gangrene and amputation of limb. Besides, many patients affected with 
PAOD develop an higher risk to die because of heart attack and stroke 
(https://www.heart.org; retrieved 26 February 2015).  
The main symptom is represented by leg pain during activity, known also as 
“intermittent claudication” that disappeared with the rest, but also by skin and foot 
ulcers, bluish skin, cold skin and poor nail and hair growth.  
Among the risk factors of PAOD there are the same that leading to atherosclerosis (M. 
M. Joosten et al, 2012), including cigarette smoking, diabetes mellitus, hypertension, 
dyslipidemia, hyperhomocysteinemia, inflammation, male sex and growing age (F. G. 
Fowkes et al,  2013). 
 
 
 
Figure 2: Comparison between normal and atherosclerotic arteries 
(www.britannica.com). 
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Pathogenesis and atherosclerotic process 
 
The most important mechanism underlying the develop of PAOD is atherosclerosis, that 
affects the vascularization to the lower limb. The process begins at the birth and 
continues slowly with the advancement of the age; in the early phase of the disease the 
endothelium is damaged and leads to the fatty accumulation into the inner wall of the 
arteries (tonaca intima), forming plaques or atheroma which obstruct the blood flow. 
Atheroma is composed by material including macrophages, cholesterol crystals, 
calcified lesions and free radicals. The lipids accumulate in the artery endothelium 
binding the components of the extracellular matrix of the intima, which is activated to 
invoke immune system cells, as monocytes, T lymphocytes and macrophages; these last 
ingest the lipid molecules and stimulate an inflammatory response (A. Zernecke et C. 
Weber, 2010). The presence of calcium increases the rigidity of the plaque that can 
break, attracting in turn the platelets in the breaking site. The platelets, however, block 
the red blood cells and may form a clot, causing thrombosis that occludes the vascular 
lumen (Figure 3); furthermore, if this clot breaks, it can cause serious damages, as 
angina, myocardial infarctions or stroke. 
The atherosclerosis treatment usually provides lifestyle changes, the use of ACE 
inhibitors and statins to decrease the blood pressure and blood cholesterol levels, and 
the angioplasty with stenting (V. Fuster,  2011). 
 
 
Figure 3: Plaque develop in the inner wall of the arteries, during the process of 
atherosclerosis (P. Libby et al, 2011). 
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Diagnosis and treatment of PAOD 
 
The symptoms of the patients with suspected PAOD are usually classified according to 
the classification of Leriche-Fontaine, which identifies 4 stages depending on the 
severity of the arterial failure: 
 Stage I: asymptomatic or incomplete blood vessel obstruction 
 Stage II: claudication pain in limb when walking 
 Stage III: rest pain, mainly in the feet 
 Stage IV: necrosis and/or gangrene of the limb 
Initially, the basic examination provides the evaluation of the possible pulses in the 
femoral, popliteal, pedal and posterior tibial arteries, the auscultation of the abdomen  
and the control of  the temperature, the color and the tropism of the foot. A widely and 
early used method is represented by the ABPI/ABI, the ankle brachial pressure index 
(T.W. Rooke et al, 2013) and later by the Doppler ultrasounds to evaluate the level of 
the functional involvement and trying to locate the occlusive lesion; other widely used 
methods are angiography, an imaging technique, but also the computerized tomography 
(CT) scanners or magnetic resonance angiography (MRA), a noninvasive diagnostic 
procedure that provides pictures of the vessels (Peripheral Arterial Disease at Merck 
Manual of Diagnosis and Therapy, 2010; T. Leiner, 2005). 
For the tretament of PAOD it is necessary to stop smoking and to monitor diabetes, 
hypertension and high cholesterol; besides, regular exercise should be practiced 
especially in the cases of claudication. Among the most commonly used drugs there are 
cilostazol, pentoxifylline, statins, prostanoids and others. Depending on the severity of 
ischemia, surgery also can be used: the methods most largely used are the percutaneous 
transluminal angioplasty (PTA), the atherectomy, the vascular bypass, thrombolysis, 
thrombectomy and in the most severe cases with gangrene, the amputation. 
 
 
Diabetic foot ulcer 
 
The diabetic foot ulcers (DFUs) are a common, costly and serious complication of 
diabetes mellitus (D. G. Amstrong et al, 2005; D. G. Amstrong et al, 2011) and they 
mainly affect the arterial system, where they tend to become chronic. In a diabetic 
patient and according to the International Working Group on the Diabetic Foot, DFU is 
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a deep wound that penetrates through the dermis up to the most internal vascular layer, 
below the ankle (W. J. Jeffcoate et al, 2004). The main mechanisms underlying DFUs 
develop are peripheral neuropathy and ischemia from peripheral arterial occlusive 
disease (PAOD). The causes of ischemic foot tissues can be the atherosclerosis or 
microvascular disease and in the presence of these situations, a moderate ischemia can 
lead to ulcer develop and impair healing (W. J. Jeffcoate et al, 2003; A Veves et al, 
2002). Early studies on the DFUs ignored that the presence of PAOD could be a very 
important risk factor, while today it is officially recognized as a significant cause of 
DFUs, with an important increase in the developed countries (A. I. Adler et al, 1999; D. 
G. Amstrong et al, 2011). Furthermore, according to a study performed by Morbach and 
colleagues in 2003, it has been highlighted as the patients with neuroischemic or 
ischemic disease show a major risk to have amputations, as well as a higher mortality 
rate (P. K. Moulik et al, 2003).  
Today, the main therapy for DFUs consists of restoring blood flow by angioplasty or 
bypass and the removal of the debridement and the necrotic tissue to accelerate the 
wound healing. Additional treatments have been recently introduced, such as biological 
dressing, compression therapy, physical therapy by the use of hyperbaric oxygen and 
negative pressure therapy, although the clinical results are still not satisfactory (G. 
Mulder et al, 2014). Nowadays, surgical revascularization is the gold standard for the 
tretament of arterial ulcer, but the blood flow restoration should be obviously combined 
with treatments aimed at reactivating the autologous healing processes, that resulted 
ineffective, moderating the inflammatory cell responses and promoting the local 
angiogenesis, in order to facilitate the wound healing processes (S. Valente et al, 2016).  
 
 
Epidemiology and costs of chronic non-healing wounds 
 
The prevalence rate for chronic non-healing wounds in the United States is 2% of the 
general population (C. K. Sen et al, 2009). The mean number of serious and complex 
conditions of comorbidity is 1,8/patient and among the most common there are diabetes 
mellitus (46,8%), obesity and overweight (71,3%), cardiovascular or peripheral vascular 
disease (51,3%). It is estimated that the costs of treating these wounds exceed 50 billion 
dollars per year (C. E. Fife et al, 2012) and these costs are 10 times more than the 
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annual budget of the World Health Organization (WHO). In this context, it is clear that 
the chronic non-healing wounds not only affect the quality of life of the patients, but 
they also have an important and great weight on the whole society, that is called to 
response to the costs of care. So, it is very important to focus the attention on new and 
promising therapeutic strategies aim to accelerate the wound healing process and to 
optimize costs and resources. 
 
 
Wound healing 
 
Acute wound healing consists of four phases and it is a dynamic process involving the 
coordinated actions of both resident and migratory cell populations within the 
extracellular matrix environment that leads to the repair of injured tissues. The first 
phase is hemostasis, caused by the rupture of the blood vessels; during this phase, the 
activation of thrombocytes and tissue factors lead to the formation of the clot, composed 
of a fibrin network. The second step is the inflammatory phase, during which bacteria, 
other pathogens, damaged or dead cells are removed by the phagocytosis process; in 
this phase, the clotting cascade is activated and the plateled-derived growth factor 
(PDGF) is released into the wound to induce cell migration and division during the next 
stage. The third phase is proliferation and growth of the new tissue: the angiogenesis 
promotes the formation of new blood vessels, the fibroblasts are activated to form a new 
extracellular matrix with deposition of collagen and fibronectin, the epithelial cells 
proliferate and form the new tissue in the injured site and myofibroblasts contract 
themselves (K. S. Midwood, 2003; H. G. Garg, 2000; S. Enoch et P. Price, 2004). The 
last phase is represented by the maturation and remodeling of the injured tissue, during 
which the cells not longer needed are removed by apoptosis (Figure 4); this phase can 
last from three weeks to months or years, because the healing process can be susceptible 
to interruption or failure. In fact, some wounds fail to heal in a timely and orderly 
manner, resulting in chronic non-healing wounds, especially in conditions complicated 
from the presence of venous and arterial diseases, diabetes mellitus, infections and 
metabolic deficiencies. In addition, the chronic wounds are more prevalent in older 
people due to the altered molecular and cellular characteristics of the aged skin and 
various associated co-morbidities. The frequent presence of chronic wounds does not 
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allow the complete recovery of the tissues, affecting on life quality of patients and 
healthcare costs.  
 
 
Figure 4: Schematic representation of the four phases of acute wound healing  
 
 
New therapeutic approaches in the context of wound healing 
 
For all reasons mentioned above, nowadays new therapeutic approaches or combined 
therapies are under development in order to facilitate the wound healing. It is good to 
remember that, for an efficient wound care, it is first of all essential revascularization, 
good wound care with debridement and exudates management, adequate rest, 
compression, pressure relief, skin care and new approaches and biological based 
treatments, among which there are the use of tissue engineered, the autologous 
fibroblasts, autologous adipose stromal vascular tissue, PRP gel treatments, cell therapy 
with multipotent stem cells and growth factors.  
The use of gene and cell therapies (M. Shimamura et al, 2013), as well as the use of 
natural or synthetic engineered matrices (G. Mulder et al, 2014; T. Lazic and V. 
Falanga, 2011) appear very interesting in the scientific community. Some studies refer 
about the complete wound healing after transplantation of biomimetic tissue engineered 
dermis substitutes with allogeneic keratinocytes and fibroblasts cells inside ulcerated 
tissue (H.-J. You et al, 2012; W. A. Marston et al, 2003). Other works report about the 
use of the adult mesenchymal stem cells derived from several tissues to treatment non-
healing wound thanks to their ability to differentiate in multiple mesengenic lineages, to 
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secrete several growth factors and to regulate the inflammatory processes (D. S. Kwon 
et al, 2008; Y. Wu et al, 2007; S.-K. Han et al, 2010; C. Nie, D. Yang et al, 2011; H. C. 
Lee et al, 2012).  
Among the new therapeutic approaches, single or combined growth factors including 
Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), 
Transforming Growth Factor-beta (TGF-beta), Fibroblast Growth Factor (FGF), 
Epidermal Growth Factor (EGF), Granulocyte Macrophage-Colony Stimulating Factor 
(GM-CSF) and Hepatocyte Growth Factor/Scatter Factor (HGF/SF) are largely studied 
(S. Enoch et al, 2006; S. Barrientos et al, 2014). These growth factors own multiple 
effects on tissue regeneration including cell proliferation and mobilization, extracellular 
matrix production and angiogenesis.  
 
 
Hepatocyte Growth Factor (HGF)  
 
HGF is the growth factor of the liver and it is a multifunctional and pleiotropic cytokine 
of mesenchymal origin involved in several biological responses including cell 
proliferation/survival, angiogenesis, morphogenesis, and motogenesis (K. Matsumoto 
and T. Nakamura, 1996), as well as inflammation and fibrosis inhibition (K. Okunishi et 
al, 2005; R. Gong, 2008). 
HGF exerts its actions not only in the liver, but also into a wide spectrum of cells, 
through its autocrine and paracrine activities. HGF is an 84 KDa dimeric molecule, 
essential growth factor for liver regeneration (T. Nakamura et al, 2010), while the 
product of the c-Met pro-oncogene is the receptor of HGF (D. P. Bottaro et al, 1991), 
which carries out its role, once linked to HGF, by its tyrosine-kinase activity (T. 
Nakamura et al, 2010), (Figure 5). 
c-Met is primarily expressed in epithelial cells, but few reports indicate that adult 
mesenchymal stem cells (MSCs) also express c-Met (S. Neuss et al, 2004; G. Forte et 
al, 2006; K. K. Aenlle et al, 2014). 
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Figure 5: Schematic representation of molecular structure of HGF and its receptor c-
Met (T. Nakamura and S. Mizuno, 2010; H. Zhu at al, 1994). 
 
 
Recent data of our research group have shown that patients with ulcers have an 
alteration of HGF/Met pathway (F. Vasuri et al, 2013). 
Another molecule of great interest, indirectly connected to HGF/Met pathway, is HIF-1 
(Hypoxia Inducible Factor-1). During hypoxia, HIF-1 drives the expression of several 
genes, otherwise repressed, especially growth factors, among which Met receptor itself 
(G. L. Semenza et al, 2001); HIF-1 could therefore regulate HGF/Met pathway, by 
influencing the amount of Met receptor on the cell surface (Figure 6). 
The results of this work (F. Vasuri et al, 2013) indicate that, in ulcers and condition of 
hyperglycemia and/or hypoxia, there is a general down-regulation of the HGF/Met 
pathways, with a repression of the local HGF production; in addition, also HIF-1 
stability decreases (S. B. Catrina et al, 2004). Since HGF/Met pathway plays key roles, 
among which promotion of cell growth, tissue homeostasis, neoangiogenesis, in 
conjunction with anti-inflammatory and anti-fibrogenic activities (T. Nakamura et al, 
2005), it supposes that the local or systemic application of HGF could reactive Met 
receptor, stabilizing the normal wound healing process. According to these evidences, 
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growth factor’s secretion, as HGF, could play an important role in tissue regeneration of 
ulcers, as well as HGF/Met axis could be the new target of future therapies. 
 
 
Figure 6: Pathway HGF/Met and its effects on cell processes (F. Vasuri et al, 2013). 
 
 
Platelet-rich plasma (PRP) 
 
Human derived autologous platelet-rich plasma (PRP) is also a promising wound 
healing treatment (K. M. Lacci et al, 2001), due to the mitogenic and chemoattracting 
effects exerted by growth factors released at high concentrations after platelet α-
granules degranulation (K. M. Lacci and A. Dardik, 2010). Some researches and clinical 
trials refer about a positive effect of PRP on re-epithelialization of non-healing wounds 
(V. R. Driver et al, 2006; H. S. Setta et al, 2011; T. Slesaczeck et al, 2012). PRP is 
defined as a portion of the plasma fraction of autologous blood having a platelet 
concentration above baseline (R. E. Marx, 2001), and it is used in several surgical field 
to facilitate tissue reparation by releasing locally acting growth factors, especially in the 
context of maxillofacial surgery, periodontal and oral surgery, heart bypass surgery, 
spinal surgery, etc. (P.A. Everts et al, 2006). PRP, in fact, may suppress cytokine 
release and limit inflammation, to improve tissue healing and regeneration, promoting 
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new capillary growth and accelerating epithelialization; finally, PRP has antimicrobial 
activity against several pathogens (Y.Q. Tang et al, 2002).  
PRP can also be got from umbilical cord blood unsuitable, on a quantity level, to 
conservation of Hematopoietic Stem Cells (HSCs): in this case it is about hemo-
component at topic use. In particular, recent studies have demonstrated that PRP exerts 
its anti-inflammatory effects through HGF (J. Zhang et al, 2013). PRP and HGF 
treatments suppress the IL-1β-induced gene expression of COX-1, COX-2 and mPGES-
1, and consequently protein expression of COX-1, COX-2 and PGE2. In this regard, the 
anti-inflammatory effects of PRP and HGF have mechanisms similar to those of 
NSAIDs; but, while these drugs have serious side effects, PRP is thought to be 
intrinsically safe for its autologous nature, feature to its advantage. 
In conclusion, in order to guarantee an efficient tissue regeneration in ulcers of lower-
limb, PRP derived from umbilical cord blood can also be used in replacement to FBS 
(Fetal Bovine Serum) in the culture medium, from which depends the in vitro expansion 
of ECFCs (Endothelial Colony Forming Cells). ECFCs are, indeed, an attractive target 
for new vascular regenerative therapies and an animal serum-free culture medium, for 
their in vitro isolation and expansion is greatly needed (J. Zhang et al, 2013). In this 
context and for the above-mentioned characteristics, PRP results more appropriate, if 
compared with FBS, for future use of ECFC. 
 
 
Stem Cells (SCs) 
 
The stem cells are undifferentiated cells provided with self-renewal for an undefined 
time. Under appropriate conditions and stimuli, the stem cells are able to give rise to 
several mature cellular types, through a process called multilineage differentiation. The 
stem cells can replicate them by two different mechanisms: the asymmetric and 
symmetric division. The asymmetric division lead to the origin of two daughter cells: 
one of which conserves the staminal characteristic, while the other daughter cell (the 
progenitor cell) differentiates in a mature cell. The symmetric division give rise to two 
identical daughter cells, which may be two stem cells or two progenitor cells (Figure 7). 
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Figure 7: Schematic representation of the mechanism of asymmetric and symmetric 
division. 
 
 
The stem cells can be classified as totipotent, pluripotent, multipotent and unipotent, 
based on their differentiation potential (A. J. Wagers et I. L. Weissman, 2004), (Figure 
8). Totipotent stem cells are able to give rise to embryonic and extra-embryonic tissues; 
the zygote is the totipotent stem cell, from which the three germ layers origin. 
Pluripotent stem cells are instead able to generate all cells derived from endoderm, 
mesoderm and ectoderm, but not the cells of extra-embryonic tissues; the embryonic 
stem cells (ESCs) and embryonic germ cells (EGCs) are pluripotent stem cells. Again, 
multipotent stem cells are able to differentiate into a specific subset of mature cell types, 
while unipotent stem cells differentiate into a unique specialized cell type. Finally, stem 
cells can be classified in two more important categories: the embryonic stem cells and 
the adult stem cells (O’Connor, 2008). 
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Figure 8: Stem cells hierarchy. 
 
 
Embryonic Stem Cells (ESCs) 
 
The ESCs are pluripotent cells which derive from embryo during the stage of blastocyst, 
5 days after fecundation. The blastocyst is a structure consisting of about 100 cells and 
it is composed of two parts: the external layer of cells called trophectoderm that will 
form the placenta and the inner cell mass (ICM), composed of pluripotent stem cells 
which will give rise to all cells of the organism. ESCs are immortal cells, they have 
unlimited proliferation potential, a normal karyotype and they are able to differentiate in 
a derivates of all three embryonic germ layers (Figure 9), including gut epithelium, 
cartilage, bone, smooth muscle, and striated muscle, neural epithelium, embryonic 
ganglia and stratified squamous epithelium. (J. A. Thomson, 1998). The ESCs express 
moreover high telomerase levels: telomerase is a ribonucleoprotein involved in 
maintaining telomere length and it is directly related to immortality of ESCs; compared 
to ESCs, telomerase is less expressed in diploid human somatic cells and telomeres 
reduce themselves during replicative life-span (C. B. Harley et al, 1991; C. M. Counter 
et al, 1996). Among the cell surface markers expressed by ESCs there are the Stage 
Specific Associated Antigen (SSEA–3 and SSEA-4), keratan sulfate antigens (TRA-l-
60 and TRA-1-81) and alkaline phosphatase (J. A. Thomson et al, 1995; J. A. Thomson 
et al, 1998). Furthermore, ESCs show a core transcriptional regulatory circuitry 
composed of the transcription factors OCT-4, SOX-2 and NANOG, essential for the  
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maintenance of pluripotency and self-renewal in early development of ESCs. These 
transcription factors are localized in the same portion of their target genes, where they 
regulate their expression (L. A. Boyer et al, 2005).  
ESCs were derived for the first time in 1981 from mouse embryo (M. Evans et al, 1981; 
M. Kaufman et al, 1981), and some year later J. Thomson and his research group 
developed a technique to isolate and grow in vitro human embryonic stem cells (J. A. 
Thomson et al, 1998). The usefulness of ESCs has been proposed in many contexts, 
from regenerative medicine to the tissue replacement after injury and disease; however, 
many ethical issues persist and limit their clinical applications. 
 
 
 
 
Figure 9: Embryonic stem cells and differentiation in a derivates of the three germ 
layers. 
 
 
Adult Stem Cells (Somatic Stem Cells) 
 
Adult stem cells or somatic stem cells (ASCs) are undifferentiated multipotent cells 
localized in the adult organism; they are provided of self-renewal and capability to 
differentiate in the specialized cells within the organ where they reside and they have 
the function of precursor cells. The presence of ASCs was discovered since 1960, when 
two populations of stem cells were identified in the bone marrow: the hematopoietic 
stem cells (HSCs) which give rise to all blood cells and the mesenchymal stem cells 
(MSCs) or bone marrow stromal cells that give rise to osteocytes, chondrocytes and 
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cells of connective tissue (A. J. Becker et al, 1963; J. Till et al, 1961). The main ASC 
function is replacing cells that die in the tissues after injury or disease (N. Schultz, 
2008). Later, ASCs have been found in several adult tissues including not only bone 
marrow, but also brain, spinal cord, peripheral blood, dental pulp, blood vessels, cornea, 
liver, pancreas and epithelia. Little is known about ASC origin and characterization, and 
the most of information come from studies with the mice. Two are the properties 
considered fundamental to the definition of ASCs: self- renewal, the ability to divide 
themselves through numerous cell cycles maintaining the undifferentiated state, and the 
multipotency or multidifferentiation potential, the ability to specialize themselves in 
mature cells of several tissue districts; this two properties may be characterized in vitro 
by clonogenic assays and the mechanism underlying this two properties get involved 
three molecular stem cell regulators: Notch, Wnt and TGF-β (G. Dontu et al, 2004; P. 
A. Beachy et al, 2004; M. Sakaki-Yumoto et al, 2012). Recent studies have also 
highlighted how the ASCs own some plasticity or stem cell trans-differentiation, 
referred to the ability to differentiate into cells from distinct germ layers (Figure 10). In 
fact, although it was initially thought that ASC capacity to differentiate was rather 
limited to the organ where they reside, it was subsequently discovered that ASCs from 
brain are able to differentiate in liver, cardiac and skeletal muscle cells and that stem 
cells from blood can generate stem cells of brain (G. Ferrari et al, 1998; F. Lagasse et al, 
2000; R. Galli et al, 2000). This phenomenon is visible in vitro when it is possible to 
induce stem cells isolated from a tissue into mature stem cells of other tissues, 
modifying the growth medium. ASCs reside in particular micro-environments called 
niches within the organs and here they are in a quiescent state until they are activated to 
proliferate; in the event of a disease or tissue injury, ASCs migrate outside of the niche 
and go for differentiation (E. Fuchs et al., 2004; K. Urbanek et al., 2006). 
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Figure 10: The adult stem cells (A. Uccelli et al, 2008). 
 
 
 Mesenchymal stem cells (MSCs) 
 
Mesenchymal stem cells are multipotent stromal cells (A. J. Friedenstein, 1968) able to 
differentiate in several lineages including osteoblasts, chondrocytes, adipocytes and 
myocytes, but also into other cell types from endodermic and ectodermic lineages (M. 
F. Pittenger et al, 1999). MSCs are cells derived from mesenchyme, an embryonic 
connective tissue generated from mesoderm, which differentiates into hematopoietic 
and connective tissues. MSCs are so cells belonging to mesenchyme, the connective 
tissue composed of a great amount of extracellular matrix (ECM) and the MSCs; the 
mesenchyme has an important role as support of the functional cells.  
MSCs were initially isolated from bone marrow at the end of 1800 but, as years go by, 
they were also isolated from a large variety of other tissues as placenta, cartilages, 
adipose tissue, adult muscle, bone tissues, umbilical cord blood, corneal stroma etc. (S. 
Gronthos et al, 2001; A. Asakura et al, 2001; A. Erices et al, 2000) 
Under normal culture conditions, these cells adhere to plastic, show a fibroblast 
morphology and own an high proliferative potential (E. M. Horwitz et al, 2005; D. J. 
Prockop et al, 1997); in vitro, MSCs can be characterized because they express 
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mesenchymal (CD44, CD73, CD90, CD105, HLA-G, Stro-1) and stemness markers 
(Oct-4, Nanog, Notch-1, Sox-2, KDR, c-Kit), pericyte (CD146, PDGFR-β, NG2) and 
neuronal markers (Nestin), while they show negativity for hematopoietic markers 
(CD14, CD34, CD45) (M. Dominici et al, 2006). Finally, MSCs which secrete several 
growth factors and play an important role in the regulation of inflammatory processes, 
inhibiting T cell proliferation by IFN gamma secretion (Z. Selmani et al, 2008; R. 
Maccario et al, 2005; E. Zappia et al, 2005; I. Rasmusson et al, 2005; G. Ren et al, 
2008). 
 
 
The vascular niche of mesenchymal stem cells 
 
Until not long ago, it was believed that the vessel wall was relatively quiescent. But the 
discovery of mesenchymal stem cells and progenitor cells in many tissues of the 
organism led to a re-evaluation of the vascular system and its biology. Briefly, the 
vascular wall is composed of cells of mesodermal origin, including endothelial cells 
(ECs), smooth muscle cells (SMCs) and stromal fibroblasts resident in the adventitia. 
The vascular wall consists of 3 layers: the intima, a layer in which ECS resides; the 
media, composed of many layers of SMCs and the adventitia, consisting of fibrous and 
adipose tissue, small capillaries usually named “vasa” and nerves, also called “vasa 
vasorum” (P.J. Gallagher, 1992; B. Hinz et al, 2007; E.L. Ritman et al, 2007; W. 
Warwich et al, 1989). The contribute of ECs and SMCs in the responses to injury was 
well investigated (P. Libby, 2005; R. Ross, 1999), but less it is known about of the 
progenitors from which vascular wall cells (VWCs) originate. The vessels are in fact 
exposed to multiple stresses and the VWCs can growth and participate to repair 
processes during the life in response to injuries. But also in pathological conditions, as 
atherosclerosis or abdominal aortic aneurysm, VWCs and their progenitors are actively 
involved in the disease develop. Furthermore, some differentiation commitment was 
obtained from human vascular wall resident mesenchymal stem cells (G. Pasquinelli et 
al, 2007; A. Hoshino et al, 2008; D.T. Covas et al, 2005). It is supposed that the 
vasculogenic niche, where these progenitors reside, is located in the vascular wall 
between the media and adventitia layers (Figure 11). This area probably contains stem 
cells able to differentiate into ECs, hematopoietic cells, mesenchymal stem cells and 
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immune cells (E. Zengin et al, 2006). A pivotal study of Tintut et al, demonstrated that 
mesenchymal stem cells are also present in adult animal vessels, while Pasquinelli et al, 
investigated about the presence of human vascular wall mesenchymal stem cells (hVW-
MSCs) in human thoracic aorta and other many arteries cryopreserved from healthy 
multiorgan donors (Y. Tintut et al, 2003; G. Pasquinelli et al, 2006). These studies 
described in addition the heterogeneity of the vasculogenic niche composition, in which 
different populations with stem cell characteristics are located., among which ECs, 
progenitors of SMCs, MSCs and progenitor cells of vascular wall. Finally recent 
evidences about the study of the perivascular ultrastructure identify two possible targets 
associated with MSCs, that means the pericyte and the perivascular fibroblasts, cells 
without contractile filaments and with long cytoplasmic processes. This evidence could 
demonstrate why some MSC express pericyte markers and smooth muscle actin, while 
other MSCs maintain a specific mesenchymal phenotype (M. Crisan et al, 2008; I. Joris 
et al, 1974). 
 
 
 
Figure 11: Structure of a vessel and heterogeneous composition of the vascular niche 
(D. F. Leach et al, 2015). 
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Fibroblasts and myofibroblasts 
 
The fibroblasts are spindle-shaped cells that reside in the connective tissues of several 
organs. The phenotype of these cells can vary from a non-contractile fibroblast to a 
contractile myofibroblast with a range of intermediate morphologies (Mc Anulty, 2007; 
B, Eyden, 2005). Unfortunately, a specific marker to identify fibroblast does not exist 
and this represents the major limit to investigate and study these cells. Regarding their 
origin different hypothesis have been sustained (A.E. Postlethwaite, 2004); some 
Authors believe that fibroblasts would originate from epithelial-mesenchymal transition 
(ETM) (J. Zavadil and E.P. Bottinger, 2005; K. K. Kim et al, 2006), after the loss of 
epithelial markers, as example E-cadherin. Other studies support the theory that 
fibroblasts would arise from resident fibroblast division or from circulating bone 
marrow-derived fibrocytes or, yet, from differentiating monocytes (Y. Chang et al, 
2014); others still include the origin of fibroblast from resident stem cells, such as 
hMSCs or pericytes. Fibroblasts are responsible for the maintenance of extracellular 
matrix (ECM), secreting ECM component, that means collagens, proteoglycans, 
fibronectin, tenascin and laminin. These cells also produce matrix metalloproteinases 
(MMPs) and their inhibitors, and regulate the interstitial fluid volume and pressure. 
Recently, even these cell typologies were introduced in the new therapeutic approaches 
to treat wound healing. When a tissue is injured, resident fibroblasts differentiate into 
myofibroblasts in particular in the early phase, when a granulation tissue is formed 
(Figure 12). Myofibroblasts proliferate during the proliferation phase and disappear in 
the last phase of wound healing, through a programmed cell death mechanism, also 
called apoptosis. These cells show abundant cell-matrix adhesions, intercellular 
junctions, gap junctions and contractile microfilaments, necessary in wound repair. In 
this regard, both fibroblasts and myofibroblasts play a central and critical role in wound 
healing and repair processes, since they generate traction and contractile forces 
necessary to promote wound contraction (B. Li et al, 2009). 
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Figure 12: Cutaneous wound after injury (A. J. Singer and R. A. F. Clark, 1999) 
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The study of this thesis is contextualized within the lower limb ulcers and wound 
healing issue. The lower extremity ulcerations represent a debilitating clinical situation 
that affects many people, especially over 65-year-old individuals, where the disease is 
much more prevalent (about 5%). Mostly in the presence of peripheral arterial occlusive 
disease, these patients own a higher probability to develop foot ulcers and chronic non-
healing wounds that fail to heal and the recovery of the tissues is not complete, affecting 
not only on life quality of the patients but also on the healthcare costs. The situation is 
furthermore complicated by conditions as diabetes mellitus, infections or metabolic 
deficiencies. Nowadays, the gold standard to treat diabetic foot ulcers and the associated 
chronic wounds is the surgical revascularization, even if new therapeutic approaches are 
tested in conjunction with the conventional treatment, in order to facilitate the wound 
healing process.  
Among the most promising prospects there is the use of gene and cell therapy or natural 
and synthetic engineered matrices (M. Shimamura et al, 2013; G. Mulder et al, 2014; T. 
Lazic and V. Falanga, 2011). Furthermore, many studies report about the use of adult 
mesenchymal stem cells derived from several tissues, thanks to their ability to 
differentiate in multiple lineages, secreting several growth factors and mediating the 
inflammatory processes (D. S. Kwon et al, 2008; Y. Wu et al, 2007; S.-K. Han et al, 
2010; C. Nie, D. Yang et al, 2011; H. C. Lee et al, 2012).  
Finally, many growth factors are widely experimented in the context of the lower-limb 
ulcers, as example PDGF, VEGF, TGF-beta, FGF etc, for their effects on cell 
proliferation, cell migration, extracellular matrix production and angiogenesis. One of 
the factors that is gaining relevant importance is the hepatocyte growth factor, the 
growth factor of liver; HGF is a pleiotropic and multifunctional cytokine, expressed in 
cells mainly of epithelial origin, with a several biological activities among which the 
promotion of cell growth and motility, the maintenance of tissue homeostasis, the 
promotion of self-repair of injured livers, kidneys and lungs, the induction of 
angiogenesis, tissue regeneration and protective. A work of our team reported 
interesting results about patients with chronic lower limb ischemia (CLI) in which there 
seems to be an alteration of the molecular pathway HGF/c-MET (F. Vasuri et al, 2013). 
In addition, our research group developed over the years a detailed protocol to isolate 
the human mesenchymal stem cells from vascular wall of several segments of arteries, 
where it is present a vascular niche; these arteries come from healthy donors and they 
have been cryopreserved into nitrogen liquid for at least 5 years; arteries were kindly 
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provided from Cardiovascular Tissue Bank facility, University – Hospital Sant’Orsola 
Malpighi, Bologna (S. Valente et al, 2014). Furthermore, it has been also developed a 
protocol to isolate a population of MSCs from the abdominal aortic aneurysm, where, 
the presence of mesenchymal stem cells (AAA-MSCs) was never discovered before (C. 
Ciavarella et al, 2015). These cells are altered since over-express MMP-9 and own an 
ineffective immunomodulatory capacity. 
We decided at first to focus our attention on vascular wall derived MSCs (hVW-MSCs) 
since they are potentially usable in the context of ulcers and wound healing; initially we 
tested HGF on healthy hVW-MSCs and then we functionally altered AAA-MSCs. In 
the last phase, we tried to characterize the differentiation potential of different cell types 
involved in the mechanism of tissue repair.  
The aim of the thesis is structured as follows. 
PART 1: study of HGF in vitro effect on healthy hVW-MSCs. 
During this phase, HGF was tested at different times on healthy hVW-MSCs to study its 
effects in terms of proliferation, migration, motility, angiogenesis and tissue 
remodeling.  
PART 2: HGF in vitro effect on tissue remodeling and inflammation in healthy hVW-
MSCs and in functional altered AAA-MSCs. 
HGF was tested in a pathological setting represented by AAA-MSCs isolated from 
abdominal aortic aneurysm, in particular in the issue of the tissue remodeling and 
inflammation. 
PART 3: Comparison of differentiation potential among different cell types involved in 
wound healing process. 
In the second phase of the study we decided to compare the behavior of hVW-MSCs 
with the one of normal human dermal fibroblasts and myofibroblasts, as cells involved 
in wound healing processes and tissue repair, in order to clarify the differences 
especially about their differentiation potential. For this aim we performed some 
functional assays to study angiogenic and adipogenic potential of these cells. 
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Human Vascular Wall – Mesenchymal Stem Cells (hVW-MSCs), 
Abdominal Aortic Aneurysm – Mesenchymal Stem Cells (AAA-
MSCs), Dermal Fibroblasts, Myofibroblasts (WPMY_1), human 
umbilical vein endothelial cell (HUVEC) and culture conditions 
 
Human Vascular Wall Mesenchymal Stem Cells (hVW-MSCs) and Abdominal Aortic 
Aneurysm Mesenchymal Stem Cells (AAA-MSCs) utilized in this study have been 
isolated from human arteries upon consent informed and according to the Ethic Protocol 
(APP-13-01) approved by the Local Ethics Committee of University Hospital St. 
Orsola-Malpighi of Bologna (Italy). Aneurysm tissues for AAA-MSCs isolation were 
provided by the Vascular Surgery Unit of University Hospital St. Orsola-Malpighi of 
Bologna (Italy), (C. Ciavarella et al, 2015). To realize the experiments, segments from 
carotid, thoracic and femoral arteries were used to isolate hVW-MSCs. The human 
artery segments were enzymatically digested overnight at 37°C, in rotation and within a 
solution of serum-free DMEM culture medium and 0,3 mg/mL Liberase type II (Roche, 
Milan, Italy). After digestion, a filtration with 40-70-100 μm nylon mesh cell strainer 
was carried out (Becton Dickinson; Franklin Lakes, NJ) and the cells obtained were 
seeded and cultured in complete DMEM 20% FBS in a humidified atmosphere of 5% 
CO2 for 2-3 days, while at following passages they were cultured in complete DMEM 
10% FBS.  The cells were expanded in vitro and characterized to prove their positivity 
to mesenchymal and stemness markers (S. Valente et al, 2014).  
In this study, experiments were performed using cells taken at passages 3 and 4 and 
cultured in DMEM plus 10% of FBS with or without Hepatocyte Growth Factor/Scatter 
Factor (HGF/SF) (WHO Reference Reagent, HGF/SF, NIBSC code: 96/564, National 
Institute for Biological Standards and Control, Potter Bar, Hertfordshire, ENG 3QG) at 
different time (from 6 hrs to 7 days) and concentrations (from 2.5 to 70 ng/mL). Cell 
starvation with low percentage of serum (0.5% FBS) for 12 hrs was performed to induce 
cell cycle synchronization before pretreatment with 0.2 μM PHA-665752 inhibitor 
(Tocris Bioscience, Bristol, UK) for 12 hrs, followed by HGF/SF addition. 
Normal human dermal fibroblasts (kindly provided by Professor Francesco Alviano, 
acquired by Lonza) and a cell line of WPMY-1 (ATCC
®
 CRL-2854
™
), were also used, 
both cultered in complete DMEM with 10% FBS.  
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Human umbilical vein endothelial cells (HUVEC) were used in the in vitro tube 
formation assay as positive control of the angiogenesis process. 
All experiments were executed in triplicate. 
 
 
Proliferation assay 
 
Different methods were used to evaluate cell proliferation. 
Cell viability was investigated using Alamar Blue fluorescence assay (Invitrogen, 
Milan, Italy). The hVW-MSCs were seeded in a 12-multiwell plate at the density of 3 × 
10
4
 and cultured in complete DMEM with or without HGF/SF (2.5, 5, and 10 ng/mL) 
for 1, 3, and 7 days. The same experiment  was also conducted by the pretreatment of 
PHA-665752 inhibitor  at 0,2 μM. Alamar Blue solution (10% v/v in cultured medium) 
was added to each well at the end of treatments and incubated for 4 hrs at 37°C 
according to the manufacturer's instruction. Alamar Blue fluorescence (Ex/Em = 
540/590 nm) of three replicates in each well was measured in a Wallac VICTOR2 
multiplate reader (Perkin Elmer, Milan, Italy). In addition, a standard polystyrene well 
was used to measure the background fluorescence; this fluorescence was subtracted 
from the reading of each well (Figure 13). 
 
Figure 13: Chemical structure of Resazurin, the blue dye of Alamar Blue. The dye is a 
redox indicator that yields a colorimetric change and a fluorescent signal in response to 
metabolic activity. 
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Immunofluorescence staining was also used to assess cell proliferation, in particular 
for cycling cells expressing Ki-67 protein. hVW-MSCs were plated at a density of 6 × 
10
5
 on coverslip in 6-well plates in DMEM overnight to allow the cell confluence and 
treated with or without HGF/SF (2.5, 5, 10, and 70 ng/mL) for 6 and 24 hrs. In parallel 
experiments, additional cell-seeded glass was starved in 0.5% FBS for 12 hrs, pretreated 
with 0.2 μM PHA-665752 inhibitor, and subjected to HGF/SF exposure at the same time 
and concentrations. Untreated cells were used as a control.  
To develop the immunofluorescence staining, the cells were seeded upon the slides at 
density of 30x10
3 
in DMEM 10% FBS and cultered O/N at 37°C in incubator. The 
following day cells were washed with PBS, fixed in 2% paraformaldehyde in PBS with 
1% Tryton X-100 for 4 minutes at RT and treated for 30 minutes at RT with 1% bovine 
serum albumin (BSA), a blocking reagent for nonspecific binding. Later, the slides were 
labeled with monoclonal antibodies against nuclear transcription factor Ki-67 (1 : 100, 
Novocastra, Leica Microsystems, Wetzlar, Germany) and the intermediate filament 
Vimentin (1 : 100, Dako Cytomation, Glostrup, Denmark) for 1 hr at 37°C in a wet 
chamber; both antibodies were prepared in 1% BSA in PBS, while for negative control 
the primary antibody was not use and no fluorescence was detected. A series of washing 
were conducted and then the cells were stained with AlexaFluor-488 (1 : 250, Life 
Technology, Carlsbad, CA, USA) secondary antibody for 1 hr at 37°C in the dark and 
counterstained with Pro Long antifade reagent with DAPI (Molecular Probes, Milan, 
Italy). Finally, the slides were observed and photographed with a Leica Leica DMI6000 
B inverted fluorescence microscope (Leica Micro-systems, Wetzlar, Germany). For 
each experimental condition, the number of Ki-67 intensely stained cells as well as 
DAPI stained nuclei was manually counted on ten random fields and their values were 
expressed in percentage as ratio of Ki-67 stained cells on total cells number (Figure 14). 
 
Figure 14: Comparison between direct and indirect Immunofluorescence. 
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The cell proliferation was also evaluated with “Cell Proliferation ELISA, BrdU (colorimetric)” 
(Roche, Milan, Italy), a colorimetric immunoassay based on the measurement of BrdU 
incorporation during DNA synthesis: a non-radioactive alternative to the [3H]-thymidine 
incorporation assay (Figure 15). The cells (hVW-MSCs, dermal fibroblasts and WPMY_1) were 
seeded in a concentration of 1000 cells/well, in a 96-well plate in an incubator at 37°C, 5% CO2 
and with 90% humidity for 7 days. In a second step, BrdU was added to the cells and the cells 
were reincubated for 4hrs, to permit BrdU to be incorporated in place of thymidine into the 
DNA during its synthesis. Later, the cells were fixed, DNA was denatured and the anti-BrdU-
POD was added to bind the BrdU incorporated in the neo-synthetized DNA: the immune 
complexes were detected by the substrate reaction and the result was quantified by 
measuring absorbance at the respective wavelength using a scanning multiwall 
spectrophotometer. The absorbance values were directly correlated to the amount of DNA 
synthesis and so to the respective proliferating cells. 
 
 
Figure 15: Schematic representation of BrdU colorimetric assay. 
 
 
Multilineage differentiation assays 
 
In vitro Tube formation assay 
 
To evaluate angiogenic potential, hVW-MSCs (isolated from carotid, thoracic and 
femoral arteries), dermal fibroblasts and WPMY_1 were seeded at confluence, starved 
with DMEM+2%FBS and treated with HGF/SF (0, 5, 10, 25, 50 ng/mL) and Vascular 
Endothelial Growth Factor (VEGF) at concentration of 50 ng/mL for 7 days in DMEM 
2% FBS. Untreated cells, cultered in DMEM 10% FBS, were used as negative control. 
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At the end of induction, the cells were seeded at concentration of 15x10
3 
in
 
a 96-well 
plate, previously coated with a semisolid matrix (Matrigel, BD Bioscences) for 1 hr at 
37°C in an incubator. Capillary-like structure formation was observed at inverted light 
microscopy after 2, 4 and 6 hrs and photographed. Two different methods were used to 
quantify the in vitro angiogenesis, within the two parts in which the thesis is structured. 
To quantify the angiogenesis, the number of capillary-like structures was manually 
counted on digitalized images taken at 4x magnification for each experimental 
condition. In parallel experiments, flow cytometry was performed to detect the 
expression of vWF, KDR, and CD31 mature endothelial cell markers in the controls, as 
well as the growth factors-treated cells. For surface antigen, the treated cells were rinsed 
in PBS, labeled with primary antibodies against KDR-APC and CD31-PE. To reveal 
vWF expression, the cells were fixed and permeabilized with the IntraPep Kit 
(Beckman-Coulter), incubated with von Willebrand Factor (vWF; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and subsequently incubated with anti-mouse 
IgG-FITC (Dako) secondary antibody. The endothelial lineage commitment was 
quantified in all experimental conditions attributing a score from 0 to 4, according to the 
flow cytometry values of each mature endothelial cell marker. The final values are 
reported as mean. 
 
Adipogenic assay 
 
For adipogenic assay, hWV-MSCs, dermal fibroblasts and WPMY_1 were seeded at the 
density of 40x10
3
 on 6-well plates. The cells were exposed to specific induction media 
according to the manufacturer’s instructions (StemPro Adipogenesis differentiation kit, 
Life Technologies) for 14 days while the control cells were cultered in 6-well plates 
with DMEM 10% FBS. The assay was carry out in double for the analysis with Oil Red 
O staining. After induction, the cells were phormalin-fixed and stained with Oil Red O 
to underline cytoplasmic lipidic droplet formation. The staining was observed at 
inverted light microscopy and photographed. 
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RNA extraction, Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) and Real Time- PCR 
  
Total RNA was extracted from hVW-MSCs, AAA-MSCs, dermal fibroblasts and 
WPMY_1 using TRIreagent according to the manufacturer’s instructions (TRIzol 
reagent; Invitrogen). Also for hVW-MSCs and AAA-MSCs treated with HGF/SF at 
different concentration (from 2.5 to 70 ng/mL) the total RNA was extracted by the same 
method. Reverse transcription of 1 μg of total RNA was carried out by a thermocycler in 
a 20 μL volume of reaction using a High Capacity Reverse Transcription Kit (Applied 
Biosystems, Carlsbad, CA, USA).  RNA amount was measured by using ND-1000 
spectrophotometer (NanoDrop, Fischer Thermo Wilmington, DE, USA). Polymerase 
Chain Reaction (PCR) products were analyzed by electrophoresis on a 2% agarose gel, 
stained with ethidium bromide and photographed under ultraviolet light. All PCR 
product sizes were identified loading a 100-base-pair (bp) DNA ladder and normalized 
to GAPDH, used as housekeeping gene.  
Real Time PCR performed in a Gene Amp 7000 Sequence Detection System (Applied 
Biosystems); the reaction was leaded in triplicate, in 20  μL volume using the SYBR 
Green mix (Life Technologies) and specific couples of primers designed  by NCBI 
BLAST tool and acquired from Sigma Aldrich (Table 1). The gene expression was 
normalized to Glyceraldehyde 3-phospate dehydrogenase (GAPDH) and expressed as 
fold changes relative to control (the comparative 2^-ΔΔCt method was used). 
The PCR primers were purchased from Sigma-Aldrich. Genes and respective primers 
are presented in Table 1 and Table 2, respectively for qualitative PCR and for Real 
Time PCR. 
 
 
 
Table 1: Couple of primers used for qualitative PCR (S. Valente et al, 2016). 
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Gene Primer sequence 
GAPDH FWD AATGGGCAGCCGTTAGGAAA 
REV AGGAGAAATCGGGCCAGCTA 
c-MET FWD GTGCCAAGCTACCAGT 
REV CTTCGTACAAGGCGTCT 
MMP-2 FWD CCCCAAAACGGACAAAGAG 
REV CTTCAGCACAAACAGGTTGC 
MMP-9 FWD GTACTCGACCTGTACCAGCG 
REV AGAAGCCCCACTTCTTGTCG 
MT1-MMP FWD CGCTGCCATGCAGAAGTTTT 
REV TGTCTGGAACACCACATCGG 
IL-10 FWD GGGGCTTCCTAACTGCTACA 
REV TAGGGGAATCCCTCCGAGAC 
TNF-alfa FWD GGATCATCTTCTCGAACCCCG 
REV CCTAGCCCTCCAAGTTCCAAG 
VE-cadherin FWD TCTTCACCCAGACCAAGTACA 
REV GGCTCATGTATCGGAGGTCG 
 
Table 2: Couple of primers utilized for Real Time PCR. Abbreviations: c-MET, 
hepatocyte growth factor receptor; GAPDH, glyceraldehyde 3 phosphate 
dehydrogenase; IL, interleukin; LPT: leptin; MMP, matrix metalloproteinases; TNF-
alpha, tumor necrosis factor alpha; VE-cadherin: vascular endothelial-cadherin.  
 
 
In Vitro Wound Healing Assay – Scratch assay 
 
Cell migration was investigated using a scratch assay. hVW-MSCs were seeded in 12-
multiwell plate at a density of 1 × 10
5
/well and grown until to confluence. Cell 
monolayers were wounded with a p200 pipette tip, washed with PBS to remove cell 
debris, and treated with complete DMEM containing HGF/SF (2.5, 5, 10, and 
70 ng/mL) for 24 hrs. In further experiments, cells were starved, inhibited with 0.2 μM 
PHA-665752, and cultured in presence of HGF/SF at the same time and concentrations. 
At the end of HGF/SF treatment for both experiments, cells were fixed in absolute 
methanol for 10 minutes, washed in PBS, stained with 0.1% Crystal Violet in 25% 
methanol for 30 minutes, and air-dried; all steps were performed at RT. The wound 
closure was observed under a phase-contrast light microscope (LM) equipped with a 
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digital camera (Nikon), acquiring images for each sample at time 0 and 24 hrs, 
respectively, using Software NIS-elements D3.2 Nikon (Tokyo, Japan). Computer-
assisted image analysis (Image-Pro Plus software, Media Cybernetics, 
http://www.mediacy.com) was employed to perform the quantification of the area of 
cells migrated into scratched area as well as the total wounded area in three different 
fields. Values were expressed in percentage as ratio of migrated cell area on total 
scratched area. Additional cell-seeded glasses were used for Vimentin intermediate 
filaments immunofluorescence staining. 
 
 
Transwell Migration Assay 
 
The cellular ability to migrate through a porous membrane under the influence of a 
chemoattractant factor was evaluated using transwell chambers (Costar, Corning 
Incorporated, NY, USA). Briefly, 500 μL of DMEM with 10% FBS with or without 
chemoattractant HGF/SF (10 ng/mL) was placed below the polycarbonate membrane 
with 8 μm pores, while a quantity of 300 μL of cellular suspension containing 2.5 × 104 
hVW-MSCs in growth medium was plated on the upper layer of the membrane for 
24 hrs at 37°C in incubator (Figure 16). After the manual removal of the non-migrated 
cells from the upper side of the membranes, the inserts were detached from the plastic 
support using a scalpel, fixed, stained with 0.1% Crystal Violet for 30 minutes at RT, 
and mounted on glass slide. The cells migrated in the lower layer were observed using a 
Leitz Diaplan LM (Wetzlar, Germany), equipped with a video camera (JVC 3CCD 
video camera, KY-F55B, Jokohama, Japan). Digital images were acquired at 10x of 
magnification using Image-Pro Plus 6 software (Media Cybernetics). Additional 
membranes were processed for SEM analysis. 
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Figure 16: Schematic representation of transwell migration assay. 
 
 
Scanning Electron Microscopy (SEM) 
 
For SEM, samples were rinsed in 0.15 M phosphate buffer to remove the culture 
medium, fixed in 2.5% buffered glutaraldehyde (TAAB Laboratories, UK) overnight at 
4°C, washed again in phosphate buffer, postfixed in 1% osmium tetroxide in 0.1 M 
phosphate buffer, wet in distilled water, and dehydrated with increasing ethanol 
concentrations (70–100%). Each step was performed at RT for 15 minutes. For drying 
the samples, they were immersed before in a solution of 50% absolute ethanol/50% 
hexamethyldisilazane (HMDS, Fluka Analytical, Sigma, Steinheim, Germany) and after 
in pure HMDS for 30 minutes each passage at RT and finally air-dried. Before 
observation, the samples were mounted on aluminum supports (Multilab type stub pin 
1/2, Surrey, UK) using a silver paste maintaining the cell-seeding surface, coated with 
gold in a sputtering device (Quorum Q150RS, Technologies Ltd., Laughton, UK), and 
observed at 5–10 kV with a Quanta 250 (FEI Company, Milan, Italy) scanning electron 
microscope. 
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Western Blot Analysis 
 
Total cellular proteins were extracted by untreated and treated hVW-MSCs using lysis 
buffer (KH2PO4 0.1 M pH 7.5, NP-40 1%, and 0.1 mM α-glycerol phosphate, added 
with complete protease inhibitors cocktail, Roche Diagnostics) and quantified 
spectrophometrically with the Bio-Rad Protein Assay (Bio-Rad Laboratories, 
Hempstead, UK). Thirty μg proteins were subjected to 8% SDS-PAGE and transferred 
to nitrocellulose membrane (GE Healthcare Life Sciences, Amersham) at 30 mA for 
2 hrs and 30 minutes. The membrane was blocked with 5% nonfat dry milk in TBS-
tween for 1 hour at room temperature (RT), incubated with primary antibodies against 
c-Met (1: 500, Santa Cruz Biotechnologies), HGF (1 : 500, Santa Cruz 
Biotechnologies), and anti-α-actin (clone AC-74, Sigma-Aldrich) at 4°C overnight. 
Secondary antibodies (human anti-rabbit/mouse horseradish peroxidase-conjugated (GE 
Healthcare, Milan, Italy) were used at 1: 10000 dilutions for 1 h at room temperature 
(RT). Protein signal was detected using Westar ηC chemiluminescent substrate 
(Cyanagen); (Figure 17). 
 
Figure 17: Schematic representation of western blotting assay. 
 
 
Statistical analysis  
  
To analyze the results, GraphPad Prism 5.0 software (GraphPad Prism software, San 
Diego, CA) was used and the data were expressed as the means ± SEM. Statistical 
analysis among samples was determinate by Student’s t-test (for two groups of 
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samples), one-way ANOVA test and Bonferroni post-test (for more than two groups of 
samples). The value < 0.05 was considered to be statistically significant, with 95% as 
confidence intervals. Each experiment was performed in triplicate.  
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PART 1: study of HGF in vitro effect on healthy hVW-MSCs 
 
hVW-MSC Isolation and Stemness Property 
 
hVW-MSCs isolated from human arteries showed a spindle-shaped morphology and a 
marked adhesion growth. hVW-MSCs expressed mesenchymal (CD44, CD73, CD90, 
CD105, HLA-G), stemness (Stro-1, Oct-4, and Notch-1), pericyte (CD146, PDGFR-β, 
and NG2), and neuronal (nestin) markers, together with the plasticity to differentiate in 
multiple mesengenic lineages, clonogenicity, and immunomodulatory functions; details 
on their morphology, immunophenotype, and molecular and functional features are 
reported elsewhere (S. Valente et al, 2014). 
 
HGF and c-MET mRNA and Protein Expression in hVW-MSCs 
 
In a previous study, Neuss et al. demonstrated that hMSCs derived from bone marrow 
expressed HGF and its receptor, c-Met (S. Neuss et al, 2004). In this study, we verified 
whether hVW-MSCs, recovered from human arteries, also may constitutively possess 
these genes. Gene expression analysis showed that hVW-MSCs express HGF and c-
MET receptor mRNA (Figure 18). Western Blot confirmed the expression of the c-Met 
receptor in hVW-MSCs and showed increased protein levels in hVW-MSCs exposed to 
HGF/SF, especially at 10 ng/mL (24 hrs). Meanwhile, the expression of the HGF 
protein did not show evident differences under HGF/SF stimulation (Figure 18). 
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Figure 18: Basal expression of HGF and c-MET in our cell modell. (a) hVW-MSCs 
were enzymatically isolated from human arteries and, at passage 3. Basal expression of 
HGF (252 bp) and c-MET (440 bp) mRNA in hVW-MSCs, detected by qualitative 
PCR. (b) c-Met and HGF protein detection on cell lysates of hVW-MSCs exposed to 
HGF/SF (0, 2.5, 5, and 10 ng/mL) for 24 hrs (S. Valente et al, 2016). 
 
 
HGF/SF effect on hVW-MSC proliferation 
 
hVW-MSCs were exposed to 0, 2.5, 5, and 10 ng/mL of HGF/SF for 24 hrs. The cell 
proliferation was assayed by two methods: immunofluorescence for Ki-67 staining and 
Alamar Blue assay.  
Immunostaining analysis showed a decrease of hVW-MSCs exposed to HGF/SF for 24 
hrs, compared to untreated hVW-MSCs after 24 hrs of incubation. In particular, the 
percentage of cycling cells positive to Ki-67 on total DAPI cells was decreased in all the 
concentrations of HGF/SF tested.  
The fluorescence with Alamar Blue assay did not show differences between the control 
cells and hVW-MSCs treated with HGF/SF for 24 hrs in all conditions (Figure 19). 
The experiment was performed also in the presence of the c-Met inhibitor; hVW-MSCs 
were pretreated with PHA-665752 and the proliferation was evaluated with the same 
methods after the HGF/SF addition. From the obtained results, we can see that the 
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HGF/SF addition to hVW-MSCs pretreated with PHA restored the normal proliferation 
and the results overlapping with those of the first series (Figure 20). 
These data confirmed that the treatment with HGF/SF has no effect on hVW-MSCs. 
 
 
Figure 19: Proliferative effect of HGF/SF on hVW-MSCs. (a) Representative pictures 
of cycling cells without and with HGF/SF treatment. Digital images were taken at 10X 
of magnification and nuclei were labeled with DAPI in blue (S. Valente et al, 2016). (b) 
In vitro proliferation of hVW-MSCs exposed to HGF/SF assessed by 
immunofluorescence staining for Ki-67 up to 24 hrs. For each experimental condition, 
the number of ki-67 intensely stained cells and DAPI stained nuclei were manually 
counted on ten randomly field. Their values expressed as ratio of ki-67-stained cells to 
total cells (c) Evaluation of cell proliferation by Alamar Blue assay for 24 hrs. 
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Figure 20: Proliferative effect of HGF/SF on PHA-665752 pretreated hVW-MSCs. (a) 
The graph shows the percentage of cycling cells Ki-67 positive, pretreated with PHA 
and then exposed to HGF/SF at different concentrations. (b) Cell viability evaluated by 
Alamar Blue assay on PHA-pretreated and HGF/SF-treated hVW-MSCs  
 
 
HGF/SF effect on hVW-MSC migration 
 
To investigate the in vitro HGF/SF effect on cell migration, we used a wounded 
confluent monolayer of hVW-MSCs, cultured for 24 hrs in presence and not of 
HGF/SF. hVW-MSCs exposed to HGF/SF at different concentrations (2.5, 5 and 10 
ng/mL) covered the wounded area more efficiently than untreated controls. The 
experiment was performed also with the addition of 0.2 μM of the c-Met inhibitor, 
PHA-665752, before the HGF/SF treatment. Nevertheless, in absence of HGF/SF 
stimuli, hVW-MSCs displayed a spontaneous capacity to migrate into the cell-free 
wounded area; the spontaneous migration was probably related to an autocrine 
mechanism due to endogenous HGF release. The addition of HGF/SF to PHA-
pretreated hVW-MSCs did not completely restore the hVW-MSCs migration. To 
validate the light microscopy results, SEM investigation was performed at the same 
concentrations and time of HGF/SF treatment. SEM confirmed the high efficacy of 
HGF/SF to promote hVW-MSC migration into wounded area restoring the cell 
monolayer scratched; similar results were obtained using single immunofluorescence 
staining for Vimentin. The Vimentin was normally expressed in all hVW-MSCs, but the 
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labeling fluorescence intensity was higher in hVW-MSCs migrated in the scratched area 
and this is probably due to a cytoskeleton remodeling process inducted by HGF/SF 
(Figure 21). 
  
Figure 21: Migratory effect of HGF/SF on hVW-MSC. (a) Representative pictures at 
light microscopy show that hVW-MSC exposed to HGF/SF revealed a higher capacity 
to migrate in the wounded area, compared to untreated cells. Wounded area is delimited 
by black lines. (b) Crystal Violet staining of hVW-MSCs migrated into the scratch area 
after 24 hrs of addition of HGF/SF, compared to the untreated hVW-MSCs. Wounded 
area is delimited by black lines. Scale bars = 50  m. (c) Immunofluorescence staining 
for Vimentin revealed that the intermediate filaments was markedly stained in migrated 
cells, compared to un-migrated cells. Scale bars = 100  m. The reported images are 
representative of three independent experiments (S. Valente et al, 2016). 
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HGF/SF effect on hVW-MSC motility 
 
The HGF/SF ability to mobilize and chemoattract hVW-MSCs was tested through a 
transwell migration assay. Crystal Violet dye showed that HGF/SF at concentration of 
10 ng/mL enhanced hWV-MSC motility when compared to spontaneous hVW-MSC 
migration. At SEM, the main of hVW-MSCs rested on the seeding surface if un-treated 
with HGF/SF; conversely, hVW-MSCs efficiently populated the migration surface after 
the addition of 10 ng/mL of HGF/SF (Figures 22). 
 
Figure 22: Motility effect of HGF/SF on hVW-MSCs. Representative Crystal Violet 
and SEM images of (a) untreated (hVW-MSCs) and (b) HGF/SF- treated hVW-MSCs. 
The cells migrated through an 8  m porous membrane adhering to the migration 
surface. The HGF/SF ability as chemoattractant facilitated the migration of hVW-
MSCs. Histological and SEM images: scale bars = 50  m (S. Valente et al, 2016). 
 
 
HGF/SF effect on hVW-MSC angiogenic differentiation 
 
The HGF/SF effect on hVW-MSCs angiogenic differentiation was evaluated through 
the in vitro tube formation assay. hVW-MSCs were induced for 7 days with HGF/SF at 
10 ng/mL or VEGF at 50 ng/mL and at the end of induction the cells were seeded in a 
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3D semisolid matrix. The capillary-like structures were photographed at light 
microscopy at 2, 6 and 24 hrs; at 2 hrs, the cells aligned from the cell periphery forming 
tube structures, while at 6 hrs the density of capillary-like network was more evident. 
Furthermore, at 24 hrs the capillary structures decreased in all samples but they 
remained still visible in hVW-MSCs induced with HGF/SF. HUVEC were used as 
positive control, because they spontaneously formed a capillary-like network. These 
structure were more evident in the induced samples, compared to untreated hVW-MSCs 
and in in addition, they were more pronounced in HGF/SF-treated cells rather than 
VEGF-treated cells (Figure 23). A further experiment was conducted by flow cytometry 
and it revealed that the mature endothelial markers (vWF, KDR and CD31) were more 
expressed after HGF/SF and VEGF stimulation. HGF/SF particularly induced an higher 
expression of vWF in confront to VEGF, while KDR and CD31 were similar in both 
conditions. Finally, hVW-MSCs treated with HGF/SF and VEGF showed a high 
endothelial commitment, overlapping to HUVEC, while the untreated hVW-MSCs 
preserved the mesenchymal identity (Figure 24). 
 
Figure 23: HGF/SF effect on hVW-MSCs angiogenic differentiation. (a) 
Representative pictures of HGF-treated hVW-MSCs when seeded in a semisolid matrix 
of matrigel. HGF/SF at 10 ng/ml and VEGF at 50 ng/ml were able to induce the 
formation of a high quantity of capillary-like structured. (b) At 24 hrs after the seeding 
on matrigel, hVW-MSCs treated with HGF/SF at 10 ng/ml still showed the capillary-
like network, in confront of the positive control (HUVEC) and VEGF-treated hVW-
MSCs. Scale bars = 100  m (S. Valente et al, 2016). 
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Figure 24: Angiogenic effect of HGF/SF on hVW-MSCs. (b) The quantitative analysis 
of the capillary-like structures revealed a higher number of tubes in hVW-MSCs treated 
with HGF/SF rather than VEGF-treated cells. *   value < 0.05; Student’s t-test. (c) 
Flow cytometry analysis of vWF, KDR, and CD31 expression on untreated hVW-
MSCs, HGF/SF- and VEGF-treated cells, and HUVEC (S. Valente et al, 2016). 
 
 
Angiogenic induction enhances VE-cadherin expression 
 
A further experiment was performed on hVW-MSCs treated with increasing 
concentrations of HGF/SF (0, 10, 25 and 50 ng/mL) for 7 days. Total RNA was 
extracted after the induction for the analysis of the expression of VE-cadherin, a typical 
marker of endothelial cells. A Real Time PCR assay was conducted and the results are 
reported in the Figure. The data show that the angiogenic induction enhanced VE-
cadherin expression until the concentrations of 25 ng/ml. At 50 ng/mL of HGF/SF, the 
expression of this marker decreases (Figure 25). 
  Results 
  55 
 
Figure 25: VE-cadherin expression in hVW-MSCs treated with HGF/SF at different 
concentration (0, 10, 25 and 50 ng/mL). The expression of VE-cadherin increases until 
25 ng/mL of HGF/SF induction. 
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PART 2: HGF in vitro effect on tissue remodeling and inflammation in 
healthy hVW-MSCs and in pathological AAA-MSCs 
 
HGF/SF effect was later investigated in the context of tissue remodeling. Based on the 
evidences in the literature, we wanted to test HGF on our cell model (hVW-MSCs) to 
verify if the exogenous stimulus with the growth factor could influence the expression 
of some molecular markers involved in tissue remodeling and if its receptor could be 
modulated after the stimulation. hVW-MSCs were so treated with HGF/SF at different 
concentrations (10, 25 and 50 ng/ml) for 24 hrs and then, total RNA was extracted to 
analyze, by using Real Time PCR, the mRNA expression of c-MET and matrix 
metalloproteinases: MMP-2, MMP-9 and MT1-MMP. From the obtained results, we 
can observe that HGF/SF has no influence on the molecular expression of these markers 
(Figure 26). 
 
 
 
Figure 26: mRNA relative expression by Real Time PCR of some tissue repair 
molecular markers: c-Met, MMP-2, MMP-9 and MT1-MMP. The results are expressed 
as fold changes relative to the control (hVW-MSCs). 
At this point of the study, we decided to test HGF/SF in a context different from healthy 
hVW-MSCs, testing its action in a pathological model. AAA-MSCs isolated from 
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abdominal aortic aneurysm according to the protocol developed by C. Ciavarella et al. 
(2015) represented a good and available model to test HGF/SF. Surprisingly, in 
pathological environment, HGF is able to influence the expression of the same markers 
evaluated in healthy context. On these pathological cells, we analyzed the same 
molecular markers evaluated in the healthy hVW-MSCs, after rHGF treatment. From 
the obtained results, significant differences can be observed in the c-MET and MMP2 
expression, above at 50 ng/ml of HGF/SF (Figure 27). 
 
 
 
Figure 27: mRNA relative expression of c-MET, MMP-2, MMP-9 and MT1-MMP in 
AAA-MSCs treated for 24 hrs with HGF/SF at different concentration. The results are 
expressed as fold changes relative to the control (AAA-MSCs). The statistical 
differences were obtained by one-way ANOVA with multiple comparison among all the 
experimental conditions. *p<0.05, **p<; 0.01. 
Finally, HGF/SF was tested on healthy hVW-MSCs and AAA-MSCs relatively to its 
influence on two cytokines involved in the inflammation processes: IL-10 and TNF-
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alfa. hVW-MSCs were treated with HGF/SF at different concentration (5, 10, 50 
ng/mL), but from the molecular analysis on the cytokine expression, no difference was 
observed in the mRNA relative expression. Conversely, in AAA-MSCs HGF/SF seems 
to reduce IL-10 and TNF-alfa expression until the concentration of 25 ng/mL; upon this 
concentration HGF/SF strongly induced the cytokine expression (Figure 28). 
 
 
Figure 28: comparison of HGF/SF effect between healthy hVW-MSCs (upper part of 
the graph) and pathological AAA-MSCs (lower part of the graph). The expression of 
IL-10 and TNF-alfa is not influence by HGF/SF treatment in hVW-MSCs, while it is 
reduced in AAA-MSCs until 25 ng/mL. The results are expressed as fold changes 
relative to the control (hVW-MSCs and AAA-MSCs). The statistical differences were 
obtained by one-way ANOVA with multiple comparison among all the experimental 
conditions. ***p<0.001. 
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PART 3: Comparison of differentiation potential among different cell 
types involved in wound healing process  
 
Cell proliferation  
 
hVW-MSCs isolated from different segments of human arteries, dermal fibroblasts and 
WPMY_1 represent promising candidates for wound healing and tissue repair.  
We cultered these cells for 7 days and the BrdU incorporation revealed some 
differences in the cell proliferation of these cells. hVW-MSCs characterization has been 
previously described (S. Valente et al, 2014). No difference between thoracic and 
femoral hVW-MSCs was showed, while a very significant increase in dermal fibroblast 
and WPMY_1 proliferation was visible (Figure 29). 
 
 
Figure 29: Evaluation of cell proliferation among hVW-MSCs derived from thoracic 
and femoral arteries, dermal fibroblasts and WPMY_1. BrdU incorporation during 
DNA synthesis; the proliferation was much higher for dermal fibroblasts and WPMY_1 
in comparison to thoracic and femoral hVW-MSCs. Results are expressed as mean ± 
standard deviation and they are representative of at least three independent experiments 
(ordinary one-way ANOVA test and Bonferroni post-test; ***, p<0.001).  
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Angiogenic and adipogenic potential among thoracic hVW-MSCs, 
femoral hVW-MSCs, dermal fibroblasts and WPMY_1 
 
Our preliminary results also show that hVW-MSCs isolated from thoracic and femoral 
arteries, human dermal fibroblasts and WPMY own a different differentiation potential.  
To analyze angiogenic potential we induced these cells with 50 ng/mL for  7 days, 
similarly to the experiments conducted for the study of HGF/SF effects. After the 
induction, the cells were seeded on semisolid matrix of matrigel and photographed at 2, 
4 and 6 hrs. From the pictures, it is possible to observe that the angiogenic potential of 
hVW-MSCs is much higher rather than the stromal counterpart. The formed capillary-
like network is more prominent in mesenchymal stem cells, while the VEGF induction 
has no effect on the formation of tube-like structures. Conversely, on WPMY_1, VEGF 
induction has a slight angiogenic effect. 
Likewise, thoracic and femoral hVW-MSCs, human dermal fibroblast and WPMY_1 
were inducted for adipogenic commitment with a specific medium for 21 days. At the 
end of induction, the cells were staining with Oil Red O and observed at the light 
microscopy. Also in this case, hVW-MSCs revealed an higher adipogenic potential 
when compared to dermal fibroblasts and WPMY. The first type is able to form lipid 
droplets under specific induction, while in the second type of cells, the induction for 
adipogenic commitment has no effect (Figure 30). 
 
 
Figure 30: Representative pictures of angiogenic and adipogenic potential among 
hVW-MSCs, human dermal fibroblasts and WPMY_1. 
  
  Discussion 
  61 
 
 
 
 
Discussion 
  
  Discussion 
  62 
Lower limb ulcers associated to peripheral arterial occlusive disease represents a 
debilitating clinical situation that affect predominantly the older population. In 
concomitance with the presence of other co-morbidity, as diabetes mellitus, infections 
or metabolic deficiencies, these patients show an higher probability to develop foot 
ulcers and more generally chronic non healing wounds that fail to heal. The recovery of 
the tissues is very difficult and nowadays the gold standard in the treatment of the 
disease remains the surgical revascularization. Nevertheless, many studies refer about 
the use of new and promising therapeutic approaches and strategies, among which the 
gene and cell therapy, engineered dermis substitute implantation (M. Shimamura et al, 
2013; G. Mulder et al, 2014), stem cells transplantation (S.-K. Han et al, 2010; C. Nie et 
al, 2011; H. C. Lee et al, 2012; E. V. Badiavas and V. Falanga, 2003), topical 
application of human platelet-derived products (V. R. Driver et al, 2006; H. S. Setta et 
al, 2011; T. Slesaczeck et al, 2012) and growth factors such as PDGF, VEGF, TGB-
beta, FGF, EGF, and GM-CFS (S. Enoch et al, 2006; S. Barrientos et al, 2014).  Among 
these growth factors, we decided to focus our attention on HGF/SF,  a multifunctional 
protein involved in the wound healing (K. Conway et al, 2006), explicating its action on 
cell mitogenesis, motogenesis, morphogenesis, repair and regeneration via c-Met 
receptor. Furthermore, HGF/SF is a very promising factor also for its antiapoptotic, 
anti-inflammatory, antifibrotic and proangiogenesis properties (T. Nakamura and S. 
Mizuno, 2010; F. Bussolino et al, 1992; S.-I. Hayashi et al, 1999). At last, a study of our 
research group reported that the patients critical limb ischemia have an alteration in the 
axis HGF/c-Met (F. Vasuri et al, 2013). Based on these evidences, we supposed that the 
exogenous administration of HGF could reactivate the c-Met receptor, facilitating the 
tissues healing. 
So, in our study, we explored the HGF/SF effects on human mesenchymal stem cells 
isolated in our laboratory from human artery vascular wall, to investiagte a possible 
mechanism able to improve the wound healing and to understand if HGF can contribute 
to the mobilization of hVW-MSCs.  
The first data showed that HGF and its c-Met receptor are constitutively expressed in 
our cell model, both at the mRNA and protein level. A slight increase of c-Met is in 
particular revealed after HGF exposure for 24 hrs, especially at 10 ng/mL.  
Regarding HGF effect on cell proliferation, we observed that HGF slightly reduced 
hVW-MSCs proliferation especially at 24 hrs after the treatment with 10ng/mL. The 
experiment was also conducted with PHA-65752, an antagonist of c-Met receptor, 
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demonstrating that this effect was independent from the activation of the HGF/SF axis. 
So, we can say that, unlike what originally thought, HGF does not exert a significant 
influence on hVW-MSCs proliferation via c-Met receptor. This is in part demonstrated 
in literature, where HGF would seem to be cell and tissue dependent (S. Neuss et al, 
2004; F. Bussolino et al, 1992; J.-M. Zahm et al, 2000; R. Ramanujum et al, 2013; R. 
Joplin et al, 1992) and where some studies refer about the inhibition of MSCs 
proliferation through the cell cycle arrest after HGF treatment (G. Forte et al, 2006; K. 
Chen et al, 2011). 
The analysis of migration by scratch assay was conducted through the evaluation of the 
repopulation of the damage area. This effect on hVW-MSCs motogenesis is reported 
and studied in a wide range of cell types (S. Neuss et al, 2004; G. Forte et al, 2006; F. 
Bussolino et al, 1992; J.-M. Zahm et al, 2000). The HGF effect on wounded confluent 
monolayers of hVW-MSCs was also analyzed by SEM and Immunofluorescence. The 
results indicated that HGF increased the hVW-MSCs ability to migrate in the cell-free 
area restoring the wounded cell monolayers and the migrating cells expressed more 
intensely Vimentin, an intermediate filament of cytoskeleton, suggesting the HGF effect 
on cytoskeleton remodeling. The experiment was conducted in parallel with PHA-
665752 to demonstrate that hVW-MSCs was reduced in the presence of c-Met receptor 
inhibitor. Surprisingly, from the data hVW-MSCs revealed a spontaneous migration, 
probably related to the autocrine secretion of endogenous HGF. The transwell migration 
assays confirmed in addition the chemoattractive property of HGF. The histological and 
ultrastructural observations showed that hVW-MSCs crossed the porous membrane, use 
the cells were attracted by HGF placed at underlying bottom. This result is very 
interesting especially in the clinical context, as HGF could recruit endogenous stem 
cells. The angiogenic differentiation induced by HGF/SF stimulation, a key point in 
wound healing and tissue repair, was also investigated and compared to the 
proangiogenic factor VEGF which owns a big effect in promoting the endothelial 
commitment of hVW-MSCs (K. E. Johnson and T. A. Wilgus, 2014; G. Pasquinelli et 
al, 2007; S. Valente et al, 2014). In our study, HGF/SF was used as angiogenic 
promoter, as already mentioned in numerous studies (F. Bussolino et al, 1992; S.-I. 
Hayashi et al, 1999; S. Ding et al, 2003), in order to induce the alignment and formation 
of vessel-like structures. The assay was assessed on hVW-MSCs by an in vitro matrigel 
assay and it showed that the cells treated with HGF/SF were able to form a large 
capillary-like network. This effect was compared to the positive control (HUVEC) and 
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with the treatment with VEGF and surprisingly, the stimulation with HGF/SF at 10 
ng/mL was able to promote the formation of tube-like structure that persisted even at 24 
hrs. This result suggested that HGF/SF could act though integrins and adhesion 
molecules stabilizing the junctions among the cells. In support of this hypothesis, we 
carried out an experiment on the total RNA extracted from hVW-MSCs induced with 
HGF/SF at different concentrations. From this preliminary data, we can observe that 
HGF/SF stimulated in a dose-dependent manner the expression of one endothelial 
marker, VE-cadherin; this effect is visible until the stimulation of 25ng/mL of HGF/SF, 
concentration over which the VE-cadherin expression decreases. Furthermore, both 
HGF/SF and VEGF stimulated the expression of vWF, KDR and CD31, the typical 
markers of endothelial commitment.  
Therefore, we decided to investigate HGF/SF role on tissue repair and remodeling 
processes, analyzing the modulation of gene expression of c-Met and some matrix 
metalloproteinases (MMP-2, MMP-9 and MT1-MMP) after the stimulation with 
HGF/SF. The results indicate that the growth factor have no effect on these molecular 
markers, mainly in healthy context. The evaluation of HGF/SF influence of two 
cytokines involved in the inflammation process (IL-10 and TNF-alfa) shows similarly 
behavior. At this point of the study we wanted to investigate HGF/SF effect in a 
pathological context. We have chosen a particular context, that means the abdominal 
aortic aneurysm, because a MSC niche is present in this tissue. The AAA-MSCs are 
pathological mesenchymal stem cells which over-express MMP-9 and own an 
ineffective immunomodulatory capacity, as demonstrated by C. Ciavarella et al (2015). 
AAA-MSCs were exposed to HGF/SF stimulation and then the same markers involved 
in remodeling were analyzed; as initially supposed, in the pathological context some 
differences can be observed, in particular in c-Met and MMP-2 expression, above 50 
ng/mL of HGF/SF comparing with the expression in the control. Instead, the expression 
of inflammatory cytokines resulted decreased in the presence of HGF/SF stimulation; 
this effect is visible until 25 ng/mL of HGF/SF, suggesting a possible anti-fibrotic and 
anti-inflammatory role. Although preliminary, this data is very promising especially in 
the clinical context, where HGF/SF could be used for their properties and anti-
inflammatory applications. 
Finally, we focused our attention on other cell types, that means human dermal 
fibroblasts and myofibroblasts, in order to evaluate their differentiation potential in 
confront of hVW-MSCs isolated from different human arteries. The MSCs together 
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with the stromal counterpart including fibroblasts and myofibroblasts represent in fact 
the most promising candidates among the new therapeutic approaches to facilitate and 
treatment of foot ulcers and wound healing. From the assays on cell proliferation, we 
can observe that the proliferative capacity is more pronounced in dermal fibroblasts and 
myofibroblasts rather than in hVW-MSCs, while the data on differentation potential 
appear very interesting. We assessed two assays to evaluate the differentiation potential: 
the cells were induced for angiogenic and adipogenic commitment respectively with 
proangiogenic factor and specific medium. The obtained results show the hVW-MSCs 
own a more higher angiogenic potential compared to fibroblasts and myofibroblasts. 
Only myofibroblasts displayed a light capacity to form tube.like structures when seeded 
on the matrigel, while in dermal fibroblasts the angiogenic induction has no effect. 
Similarly, only hVW-MSCs are able to form lipid droplets when induced with a specific 
medium, suggesting their possible use in the reconstitution of the fatty tissue, always in 
the context of wound healing. 
 
According to our data, the healthy hVW-MSCs isolated from the vascular niche of 
human arteries constitutively expresses HGF and its receptor c-Met. Interestingly, the 
addition of exogenous HGF/SF enhances hVW-MSC migration, motility and capillary-
like structures formation. Furthermore, HGF/SF could also be used in different 
pathological contexts where it seems to have some anti-fibrotic and anti-inflammatory 
properties, acting on the tissue repair and remodeling processes. Finally, a preliminary 
data on the evaluation of differentiation potential put on evidence the higher hVW-MSC 
potential in terms of angiogenesis and adipogenesis, rather than in the stromal 
counterpart represented by dermal fibroblasts and myofibroblasts. 
These data could suggest a novel possible therapeutic strategy, based on the use of 
hVW-MSCs, in the light of their high differentiation potential, and on the local delivery 
of exogenous HGF/SF, which could accelerate and facilitate the healing of unresponsive 
vascular ulcers. 
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